CLINICAL TRIALS PROFILE FOR CANGRELOR
✉ Email this page to a colleague
All Clinical Trials for cangrelor
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00102674 ↗ | Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor | Completed | The Medicines Company | Phase 1 | 2005-03-01 | The purposes of this study are to: - Evaluate the tolerability of two cangrelor regimens. - Compare the PD of cangrelor regimens with oral clopidogrel. |
| NCT00305162 ↗ | A Clinical Trial to Demonstrate the Efficacy of Cangrelor | Terminated | The Medicines Company | Phase 3 | 2006-04-01 | The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI. |
| NCT00385138 ↗ | Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. | Terminated | The Medicines Company | Phase 3 | 2006-09-01 | The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a composite of all-cause mortality, myocardial infarction (MI), and ischemia-driven revascularization (IDR). |
| NCT00699504 ↗ | Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers | Completed | The Medicines Company | Phase 1 | 2008-06-01 | To assess the safety of cangrelor on cardiac repolarization as measured by electrocardiogram (ECG) at therapeutic and supratherapeutic doses. |
| NCT00767507 ↗ | Maintenance of Platelet Inhibition With Cangrelor | Completed | The Medicines Company | Phase 2 | 2008-10-01 | The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively. |
| NCT01103440 ↗ | Aspirin Resistance and Percutaneous Coronary Intervention (PCI) | Completed | Icahn School of Medicine at Mount Sinai | Phase 2 | 2007-04-01 | The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI). |
| NCT01156571 ↗ | A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX) | Completed | The Medicines Company | Phase 3 | 2010-09-01 | The study is designed to compare the efficacy and safety profile of cangrelor to standard of care in patients require percutaneous coronary intervention (PCI). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for cangrelor
Condition Name
Clinical Trial Locations for cangrelor
Trials by Country
Clinical Trial Progress for cangrelor
Clinical Trial Phase
Clinical Trial Sponsors for cangrelor
Sponsor Name
